Zimmer Biomet (ZBH) Expected to Announce Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.88 per share and revenue of $2.04 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.07 EPS. On average, analysts expect Zimmer Biomet to post $8.54 EPS for the current fiscal year and $8.98 EPS for the next fiscal year.

Zimmer Biomet Stock Up 0.0%

Shares of Zimmer Biomet stock opened at $94.54 on Monday. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $103.70. The company has a market capitalization of $18.03 billion, a PE ratio of 23.00, a P/E/G ratio of 2.27 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The business has a 50-day moving average of $94.86 and a 200-day moving average of $91.70.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling

In related news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ZBH has been the topic of several recent analyst reports. Sanford C. Bernstein upped their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Royal Bank Of Canada upped their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research report on Thursday, August 6th. Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Finally, Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $104.47.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.